During a live event, Deborah Wong, MD, PhD, discussed the role of EBV and challenges in nasopharyngeal cancer diagnosis with ...

A panelist discusses how chronic graft-versus-host disease affects 30-70% of allogeneic transplant patients across eight ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Nini Wu, MD, MBA, discusses long-term investments aimed at stabilizing and strengthening the future of community oncology ...

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the ...

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with ...